These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 27056738

  • 1. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L, ARISTOTLE and RE-LY Investigators.
    Lancet; 2016 Jun 04; 387(10035):2302-2311. PubMed ID: 27056738
    [Abstract] [Full Text] [Related]

  • 2. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.
    Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L, RE-LY and ARISTOTLE Investigators.
    Circulation; 2016 Nov 29; 134(22):1697-1707. PubMed ID: 27569438
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH.
    Lancet; 2012 Nov 17; 380(9855):1749-58. PubMed ID: 23036896
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
    Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Alings M, De Caterina R, Eikelboom JW, Ezekowitz MD, Held C, Huber K, Hylek EM, Granger CB, Lopes RD, Vinereanu D, Siegbahn A, Wallentin L.
    JAMA Netw Open; 2020 Sep 01; 3(9):e2015943. PubMed ID: 32936298
    [Abstract] [Full Text] [Related]

  • 5. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
    Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA.
    Circulation; 2019 Feb 05; 139(6):760-771. PubMed ID: 30586727
    [Abstract] [Full Text] [Related]

  • 6. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
    Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L, ARISTOTLE and RE-LY Investigators.
    Eur Heart J; 2018 Feb 07; 39(6):477-485. PubMed ID: 29069359
    [Abstract] [Full Text] [Related]

  • 7. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED.
    Eur Heart J; 2015 Dec 07; 36(46):3258-64. PubMed ID: 26424865
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas.
    Pol T, Hijazi Z, Lindbäck J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L.
    Open Heart; 2021 Mar 07; 8(1):. PubMed ID: 33741689
    [Abstract] [Full Text] [Related]

  • 9. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB, ARISTOTLE Investigators.
    J Am Coll Cardiol; 2021 Mar 07; 63(1):52-61. PubMed ID: 24055845
    [Abstract] [Full Text] [Related]

  • 10. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.
    Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L, ARISTOTLE and STABILITY Investigators.
    Eur Heart J; 2016 May 21; 37(20):1582-90. PubMed ID: 26920728
    [Abstract] [Full Text] [Related]

  • 11. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
    Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdés M, Marín F, Lip GYH.
    Thromb Haemost; 2017 Oct 05; 117(10):1848-1858. PubMed ID: 28799620
    [Abstract] [Full Text] [Related]

  • 12. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
    Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L, ARISTOTLE Investigators.
    Heart; 2016 Apr 05; 102(7):508-17. PubMed ID: 26839066
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
    Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Mărgulescu AD, Wallentin L, Atar D.
    Eur Heart J; 2015 Dec 07; 36(46):3268-75. PubMed ID: 26371113
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
    Senoo K, Proietti M, Lane DA, Lip GY.
    Am J Med; 2016 Jun 07; 129(6):600-7. PubMed ID: 26482233
    [Abstract] [Full Text] [Related]

  • 15. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, ARISTOTLE Investigators.
    Circulation; 2014 Nov 18; 130(21):1847-58. PubMed ID: 25294786
    [Abstract] [Full Text] [Related]

  • 16. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L.
    Am Heart J; 2017 Aug 18; 190():94-103. PubMed ID: 28760218
    [Abstract] [Full Text] [Related]

  • 17. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial.
    Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB, Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators.
    Am J Med; 2018 Mar 18; 131(3):269-275.e2. PubMed ID: 29122636
    [Abstract] [Full Text] [Related]

  • 18. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M, Hijazi Z, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Lane DA, Oldgren J, Roldan V, Yusuf S, Wallentin L, RE-LY Investigators.
    J Intern Med; 2018 Mar 18; 283(3):282-292. PubMed ID: 29044861
    [Abstract] [Full Text] [Related]

  • 19. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
    Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY.
    J Am Coll Cardiol; 2012 Aug 28; 60(9):861-7. PubMed ID: 22858389
    [Abstract] [Full Text] [Related]

  • 20. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH.
    Circulation; 2015 Aug 25; 132(8):624-32. PubMed ID: 26106009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.